Previous 10 | Next 10 |
home / stock / huma / huma articles
DURHAM, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univer...
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected thir...
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 100 points on Friday. Shares of Hewlett Packard Enterprise...
Humacyte, Inc. (NASDAQ:HUMA) shares are trading higher on Friday. The company announced that the U.S. FDA has accepted and granted Priori...
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. Shares of The Boeing Company (NYSE: BA) rose duri...
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univers...
DURHAM, N.C., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing unive...
DURHAM, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univer...
Humacyte Inc (NASDAQ: HUMA) released topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repa...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...